

Lifeloc Technologies
Annual Shareholders Meeting
May 17, 2023



Committed to safer roads and
workplaces worldwide

1

Welcome Shareholders

- Agenda
- Shareholder Votes per Proxy Statement
- State of the Company

2

Lifeloc Technologies

Safe Harbor Agreement

This presentation contains forward-looking statements which reflect management's expectations regarding Lifeloc's future growth, results of operations, performance (both operational and financial) and business prospects and opportunities. Where possible words such as "plans," "expects" or "does not expect," "budget," "forecasts," "anticipates" or "does not anticipate," "believes," "intends" and similar expressions or statements that certain actions, events or results "may," "could," "would," "might" or "will" be taken, occur or be achieved, have been used to identify these forward-looking statements. Although the forward-looking statements contained in this presentation reflect management's current assumptions based upon information currently available to management and based upon that which management believes to be reasonable assumptions, Lifeloc cannot be certain that actual results will be consistent with these forward looking statements. Forward-looking statements necessarily involve significant known and unknown risks, assumptions and uncertainties that may cause Lifeloc's actual results, performance, prospects and opportunities in future periods to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things: international and domestic operations, customer demand, regulatory matters credit and customer concentration; competition; rapid technological change; product liability claims; intellectual property; use of non-GAAP financial measures; significant shareholder; supply arrangements; and dependence upon key management personnel and executives. For more details, please see the "Risk Factors" section of our SEC filing.

Although Lifeloc has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Accordingly, as noted above, you should not place undue reliance on forward-looking statements. These forward-looking statements are made as of the date of this presentation and, except as required by law, Lifeloc assumes no obligation to update or revise them to reflect new events or circumstances.

3

Lifeloc Today

- Installed base in over 65 countries.
- Global penetration in both workplace testing and law enforcement
- Core Business is generally cash flow positive
- \$8.48 million sales, 2022
- Equivalent of 36 full time employees
- Big growth opportunity is real time drug testing

4

Post Pandemic

The pandemic and supply chain have dominated company agenda

- Benefit from both rounds of PPP as well as ERTC
- Sales recovered
- Supply chain challenges constrained 2022 sales
- Broad price increases

5

2022 Income Statement

Income Statement	2022	2021
Revenue	\$ 8,481,993	\$ 7,054,430
Gross Profit	\$ 3,074,951	\$ 3,060,096
Gross Margin	36.3%	43.4%
R&D	\$ 1,385,927	\$ 1,213,482
Sales	\$ 1,112,526	\$ 1,003,983
General and Admin	\$ 1,216,843	\$ 1,111,544
PPP, ERTC Benefit	\$ 107,575	\$ 936,444
Pretax Income	\$ (572,737)	\$ 619,660
Net Income	\$ (455,757)	\$ 675,967

6

6

Return to Growth

Immediate
Contributors

Now exiting the constrained supply,
ramp up sales and marketing

New Platform LX9 and LT7

Ultimate
Target

Lifeloc seeks to grow and exceed
\$100 million

With real time drug testing via SpinDx

7

New Platform LX9 and LT7



Registrations: US DOT, SAI Global
(1997 and 2019 standards),
Columbian Resolution 88919 with
more to come

LX9 is premium model with
GPS, WiFi, Bluetooth

Customization through
Configuration files and protocols

Opening opportunities through
pairing and customization

8

New Platform LX9 and LT7



LT7 is the value model

Temperature range -10°C to 55°C

Ambidextrous

This line is now sold in more than 25 countries

9

R.A.D.A.R.® Model Development

- R.A.D.A.R. 200 model has updated communication, improved mechanical reliability and GPS accuracy
- In 2022 Lifeloc explored spinoff to raise money to upgrade biometrics while not diverting resources from SpinDx
- Instead, biometrics upgrade has been outsourced, with prototypes expected later this year



R.A.D.A.R.® is a registered trademark of Lifeloc Technologies Inc.

10

10

Rapid Drug Testing

- The rapid drug testing market remains our best opportunity for major growth.
- The drug testing needs are enormous and growing.
- Growing marijuana legalization is normalizing abuse. Legalization only increases the need rapid drug detection.
- The recently issued U.S. DOT rule requiring the availability of oral fluids as a drug testing option have raised the value and urgency for the first SpinDx offering.

11

SpinDx Development

- SpinDx methodology:
 - Quantitative and sensitive
 - Discriminating for psychoactive Δ^9 -THC
 - Portable
 - Current analysis time under 20 minutes, with improvements expected
- SpinDx demonstrated to work with saliva in laboratory, correlating to LCMS
- Leverage the Lifeloc capability to design and manufacture rugged portable testers
- Lifeloc has existing channel to both Law Enforcement and Workplace markets



12


SpinDx Development Status

- Four Lifeloc designed prototypes have been built
- Hardware and assay being optimized
- R&D team expanding, with SpinDx commercialization as primary objective
- Patent application filed for enhancing Δ^9 -THC specificity beyond Sandia developments
- Graphical user interface in development



13

Start up Screen



14

Test in Progress

TEST INPROGRESS
12:30P

- Cocaine
- Methamphetamine
- Amphetamine
- THC
- Opioids
- Benzodiazepine
- Ketamine

TEST **BASIC PANEL**

SERIAL # **10-2023-0410037**

DATE **04/10/2023**

TIME **12:30 PM**

PRINT
RESULT

15

Result

TEST RESULT
12:30P

- Cocaine
- Methamphetamine
- Amphetamine
- THC
- Opioids
- Benzodiazepine
- Ketamine

TEST **BASIC PANEL**

SERIAL # **10-2023-0410037**

DATE **04/10/2023**

TIME **12:30 PM**

PRINT
RESULT

16

SpinDx Business Model

- SpinDx reader is the basis of a broad platform of rapid drug tests
- Disks for different tests different tests will be an ongoing development effort
 - Sample source: Saliva, breath, blood
 - Different drug panels
- Disks and collection kits are higher value consumables than mouthpieces
- Readers will be able to analyze future disks with firmware upgrades via subscription



17

SpinDx Next Steps

- Human, real user samples being collected for validation and optimization
- Test kit must be made roadside ready, where user collects sample, introduces to disk, and reads result
- First product release will be a reader with saliva Δ^9 -THC pass/fail analysis disk, followed by a quantitative disk
- Breath analysis disk and collection kit will follow as soon as possible



18

Lifeloc Growth Summary

Nurture the core business with feature expansion and sales expansion to maximize cash flow.

Cash flow from the core is expected to continue to fund the ultimate growth target of real time drug testing to avoid or minimize shareholder dilution.

19

Thank you Lifeloc shareholders for
your continued support

20